Mark Genovese

Rheumatologist

James W. Raitt M.D. Professor

Amyloid Center

  • 300 Pasteur Drive
  • Stanford, CA 94305
  • Phone: 650-725-6186
Learn More About the Clinic Getting Here Make An Appointment

Immunology and Rheumatology Clinic

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-723-6961
Learn More About the Clinic Getting Here Make An Appointment

Psoriasis Clinic

  • 450 Broadway Street
  • Redwood City, CA 94063
  • Phone: 650-723-6316
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Board Certification: Rheumatology, American Board of Internal Medicine (1998)

Fellowship: Stanford University Medical Center (1998) CA

Residency: Stanford University Medical Center (1996) CA

Residency: Stanford University Medical Center (1995) CA

Internship: Stanford University Medical Center (1993) CA

Medical Education: Johns Hopkins University (1992) MD

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Novel small molecule therapeutics in rheumatoid arthritis
Kelly, V., & Genovese, M. (2013). Novel small molecule therapeutics in rheumatoid arthritis. RHEUMATOLOGY, 52(7), 1155-1162.

Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
Genovese, M. C., Rubbert-Roth, A., Smolen, J. S., Kremer, J., Khraishi, M., & van Vollenhoven, R. (2013). Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. JOURNAL OF RHEUMATOLOGY, 40(6), 768-780.

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., & Mpofu, S. (2013). Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Annals of the rheumatic diseases, 72(6), 863-869.

Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
Stohl, W., Merrill, J. T., McKay, J. D., Lisse, J. R., Zhong, Z. J., & Genovese, M. C. (2013). Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study. JOURNAL OF RHEUMATOLOGY, 40(5), 579-589.

Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial
Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Jones, D. A., Musser, T. K., & Magilavy, D. B. (2013). Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial. JOURNAL OF RHEUMATOLOGY, 40(4), 369-378.

Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial
Genovese, M. C., Bojin, S., Biagini, I. M., Mociran, E., Cristei, D., & Sloan-Lancaster, J. (2013). Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial. ARTHRITIS AND RHEUMATISM, 65(4), 880-889.

Effects of sclerostin antibody on healing of a non-critical size femoral bone defect
Jawad, M. U., Fritton, K. E., Ma, T., Ren, P.-G., Goodman, S. B., & Genovese, M. C. (2013). Effects of sclerostin antibody on healing of a non-critical size femoral bone defect. JOURNAL OF ORTHOPAEDIC RESEARCH, 31(1), 155-163.

Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy
Genovese, M. C., Schiff, M., Luggen, M., Le Bars, M., Aranda, R., & DougadoS, M. (2012). Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy. JOURNAL OF RHEUMATOLOGY, 39(8), 1546-1554.

Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study
Genovese, M. C., Han, C., Keystone, E. C., Hsia, E. C., Buchanan, J., & Rahman, M. U. (2012). Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study. JOURNAL OF RHEUMATOLOGY, 39(6), 1185-1191.

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
Genovese, M. C., Fleischmann, R. M., Greenwald, M., Satterwhite, J., Veenhuizen, M., & Benichou, O. (2012). Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Annals of the rheumatic diseases.

Subcutaneous Abatacept Versus Intravenous Abatacept A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
Genovese, M. C., Covarrubias, A., LEON, G., Mysler, E., Keiserman, M., & Alten, R. (2011). Subcutaneous Abatacept Versus Intravenous Abatacept A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate. ARTHRITIS AND RHEUMATISM, 63(10), 2854-2864.

Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Antagonist Therapy Results of a Phase II, Randomized, Placebo-Controlled, Dose-Finding Trial
Genovese, M. C., Kinnman, N., de La Bourdonnaye, G., Rossi, C. P., & Tak, P. P. (2011). Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Antagonist Therapy Results of a Phase II, Randomized, Placebo-Controlled, Dose-Finding Trial. ARTHRITIS AND RHEUMATISM, 63(7), 1793-1803.

A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis
Genovese, M. C., Cohen, S. B., Wofsy, D., Weinblatt, M. E., Firestein, G. S., & Tong, S. E. (2011). A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 38(5), 846-854.

An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis A Three-Month Randomized, Placebo-Controlled, Phase II Study in Patients With Active Rheumatoid Arthritis That Did Not Respond to Biologic Agents
Genovese, M. C., Kavanaugh, A., Weinblatt, M. E., Peterfy, C., DiCarlo, J., & Magilavy, D. B. (2011). An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis A Three-Month Randomized, Placebo-Controlled, Phase II Study in Patients With Active Rheumatoid Arthritis That Did Not Respond to Biologic Agents. ARTHRITIS AND RHEUMATISM, 63(2), 337-345.

LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study
Genovese, M. C., Van den Bosch, F., ROBERSON, S. A., Bojin, S., Biagini, I. M., & Sloan-Lancaster, J. (2010). LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study. ARTHRITIS AND RHEUMATISM, 62(4), 929-939.

Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients
Genovese, M. C., Breedveld, F. C., Emery, P., Cohen, S., Keystone, E., & Shaw, T. M. (2009). Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. ANNALS OF THE RHEUMATIC DISEASES, 68(12), 1894-1897.

First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy
Schmajuk, G., & Genovese, M. C. (2009). First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy. JOURNAL OF RHEUMATOLOGY, 36(7), 1559-1560.

Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis
Emery, P., Genovese, M. C., van Vollenhoven, R., Sharp, J. T., Patra, K., & Sasso, E. H. (2009). Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 36(7), 1429-1441.

Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo
Ma, T., Ren, P.-G., Larsen, D. M., Suenaga, E., Zilber, S., & Goodman, S. B. (2009). Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 89A(1), 117-123.

Inhibition of p38: Has the Fat Lady Sung
Genovese, M. C. (2009). Inhibition of p38: Has the Fat Lady Sung. ARTHRITIS AND RHEUMATISM, 60(2), 317-320.

Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis
Hueber, W., Tomooka, B. H., Batliwalla, F., Li, W., Monach, P. A., & Robinson, W. H. (2009). Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. ARTHRITIS RESEARCH & THERAPY, 11(3).

Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., & Gomez-Rein, J. J. (2008). Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study. ARTHRITIS AND RHEUMATISM, 58(10), 2968-2980.

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
Genovese, M. C., Kaine, J. L., Lowenstein, M. B., Del Giudice, J., Baldassare, A., & Dummer, W. (2008). Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. ARTHRITIS AND RHEUMATISM, 58(9), 2652-2661.

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
Genovese, M. C., Schiff, M., Luggen, M., Becker, J.-C., Aranda, R., & Dougados, M. (2008). Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. ANNALS OF THE RHEUMATIC DISEASES, 67(4), 547-554.

Efficacy results from pivotal clinical trials with abatacept
Rozelle, A. L., & Genovese, M. C. (2007). Efficacy results from pivotal clinical trials with abatacept. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 25(5), S30-S34.

A pilot trial of rituximab in the treatment of patients with dermatomyositis
Chung, L., Genovese, M. C., & Fiorentino, D. F. (2007). A pilot trial of rituximab in the treatment of patients with dermatomyositis. ARCHIVES OF DERMATOLOGY, 143(6), 763-767.

Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines
Hueber, W., Tomooka, B. H., Zhao, X., Kidd, B. A., Drijfhout, J. W., & Robinson, W. H. (2007). Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. ANNALS OF THE RHEUMATIC DISEASES, 66(6), 712-719.

A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands
Magnano, M. D., Chakravarty, E. F., Broudy, C., Chung, L., Kelman, A., & Genovese, M. C. (2007). A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. JOURNAL OF RHEUMATOLOGY, 34(6), 1323-1327.

Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy
Genovese, M. C., Mease, P. J., Thomson, G. Td., Kivitz, A. J., Perdok, R. J., & Sasso, E. H. (2007). Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. JOURNAL OF RHEUMATOLOGY, 34(5), 1040-1050.

Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
Paniagua, R. T., Sharpe, O., Ho, P. P., Chan, S. M., Chang, A., & Robinson, W. H. (2006). Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. JOURNAL OF CLINICAL INVESTIGATION, 116(10), 2633-2642.

A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis
Genovese, M. C., Chakravarty, E. F., Boyle, D. L., Tutuncu, Z., Thorburn, C. M., & Kavanaugh, A. (2005). A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. JOURNAL OF RHEUMATOLOGY, 32(12), 2345-2350.

Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis.
Magnano, M. D., & Genovese, M. C. (2005). Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis. Current rheumatology reports, 7(5), 407-415.

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
Genovese, M. C., Becker, J., Schiff, M., Luggen, M., Sherrer, Y., & Dougados, M. (2005). Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. NEW ENGLAND JOURNAL OF MEDICINE, 353(11), 1114-1123.

Antigen microarray profiling of autoantibodies in rheumatoid arthritis
Hueber, W., Kidd, B. A., Tomooka, B. H., Lee, B. J., Bruce, B., & Robinson, W. H. (2005). Antigen microarray profiling of autoantibodies in rheumatoid arthritis. ARTHRITIS AND RHEUMATISM, 52(9), 2645-2655.

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis
Genovese, M. C., Bathon, J. M., Fleischmann, R. M., Moreland, L. W., Martin, R. W., & Leff, J. A. (2005). Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. JOURNAL OF RHEUMATOLOGY, 32(7), 1232-1242.

Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus
Chakravarty, E. F., Colon, I., Langen, E. S., Nix, D. A., El-Sayed, Y. Y., & Druzin, M. L. (2005). Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 192(6), 1897-1904.

Biologic therapies in clinical development for the treatment of rheumatoid arthritis
Genovese, M. C. (2005). Biologic therapies in clinical development for the treatment of rheumatoid arthritis. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 11(3), S45-S54.

Temporal effects of a COX-2-selective NSAID on bone ingrowth
Goodman, S. B., Ma, T., Mitsunaga, L., Miyanishi, K., Genovese, M. C., & Smith, R. L. (2005). Temporal effects of a COX-2-selective NSAID on bone ingrowth. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 72A(3), 279-287.

Pharmacologic modulation of periprosthetic osteolysis
Goodman, S. B., Trindade, M., Ma, T., Genovese, M., & Smith, R. L. (2005). Pharmacologic modulation of periprosthetic osteolysis. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, (430), 39-45.

Associations between rheumatoid arthritis and malignancy
Chakravarty, E. F., & Genovese, M. C. (2004). Associations between rheumatoid arthritis and malignancy. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 30(2), 271-?.

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
Genovese, M. C., Cohen, S., Moreland, L., Lium, D., Robbins, S., & Bekker, P. (2004). Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. ARTHRITIS AND RHEUMATISM, 50(5), 1412-1419.

Treatment of rheumatoid arthritis with etanercept
Genovese, M. C., & Kremer, J. M. (2004). Treatment of rheumatoid arthritis with etanercept. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 30(2), 311-?.

Unlocking the "PAD" lock on rheumatoid arthritis
Utz, P. J., Genovese, M. C., & Robinson, W. H. (2004). Unlocking the "PAD" lock on rheumatoid arthritis. ANNALS OF THE RHEUMATIC DISEASES, 63(4), 330-332.

A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626].
Genovese, M. C., Chakravarty, E. F., Krishnan, E., & Moreland, L. W. (2004). A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Arthritis research & therapy, 6(1), R73-R77.

Interleukin 1 receptor antagonist inhibits localized bone formation in vivo
Ma, T., Miyanishi, K., Trindade, M. Cd., Genovese, M., Regula, D., & Goodman, S. B. (2003). Interleukin 1 receptor antagonist inhibits localized bone formation in vivo. JOURNAL OF RHEUMATOLOGY, 30(12), 2547-2552.

COX-2 selective inhibitors and bone
Goodman, S. B., Ma, T., Genovese, M., & Smith, R. L. (2003). COX-2 selective inhibitors and bone. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 16(3), 201-205.

Imaging of the articular cartilage in osteoarthritis of the knee joint: 3D spatial-spectral spoiled gradient-echo vs. fat-suppressed 3D spoiled gradient-echo MR imaging
Yoshioka, H., Alley, M., Steines, D., Stevens, K., Rubesova, E., & Lang, P. (2003). Imaging of the articular cartilage in osteoarthritis of the knee joint: 3D spatial-spectral spoiled gradient-echo vs. fat-suppressed 3D spoiled gradient-echo MR imaging. JOURNAL OF MAGNETIC RESONANCE IMAGING, 18(1), 66-71.

Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles
Goodman, S., Trindade, M., Ma, T., Lee, M., Wang, N., & Smith, R. L. (2003). Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 65A(1), 43-50.

Rheumatic syndromes associated with malignancy
Chakravarty, E., & Genovese, M. C. (2003). Rheumatic syndromes associated with malignancy. CURRENT OPINION IN RHEUMATOLOGY, 15(1), 35-43.

COX-2 selective NSAID decreases bone ingrowth in vivo
Goodman, S., Ma, T., Trindade, M., Ikenoue, T., Matsuura, I., & Smith, R. L. (2002). COX-2 selective NSAID decreases bone ingrowth in vivo. JOURNAL OF ORTHOPAEDIC RESEARCH, 20(6), 1164-1169.

Central nervous system lupus and pregnancy: 11-year experience at a single center.
El-Sayed, Y. Y., Lu, E. J., Genovese, M. C., Lambert, R. E., Chitkara, U., & Druzin, M. L. (2002). Central nervous system lupus and pregnancy: 11-year experience at a single center. journal of maternal-fetal & neonatal medicine , 12(2), 99-103.

Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes
Genovese, M. C., Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., & Finck, B. K. (2002). Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes. ARTHRITIS AND RHEUMATISM, 46(6), 1443-1450.

Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis
Genovese, M. C., Uhrin, Z., Bloch, D. A., Oehlert, J., Sibley, R. K., & Strober, S. (2002). Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis. ARTHRITIS AND RHEUMATISM, 46(4), 1014-1018.

Autoantigen microarrays for multiplex characterization of autoantibody responses
Robinson, W. H., DiGennaro, C., Hueber, W., Haab, B. B., KAMACHI, M., & Utz, P. J. (2002). Autoantigen microarrays for multiplex characterization of autoantibody responses. NATURE MEDICINE, 8(3), 295-301.

Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes
Kunkel, E. J., Boisvert, J., Murphy, K., Vierra, M. A., Genovese, M. C., & Campbell, J. J. (2002). Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. AMERICAN JOURNAL OF PATHOLOGY, 160(1), 347-355.

Rules of chemokine receptor association with T cell polarization in vivo
Kim, C. H., Rott, L., Kunkel, E. J., Genovese, M. C., Andrew, D. P., & BUTCHER, E. C. (2001). Rules of chemokine receptor association with T cell polarization in vivo. JOURNAL OF CLINICAL INVESTIGATION, 108(9), 1331-1339.

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism - By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?
Robinson, W. H., Genovese, M. C., & Moreland, L. W. (2001). Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism - By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. ARTHRITIS AND RHEUMATISM, 44(9), 1977-1983.

Treatment of rheumatoid arthritis with total lymphoid irradiation - Long-term survival
Uhrin, Z., Wang, B. We., Matsuda, Y., Strober, S., & Genovese, M. C. (2001). Treatment of rheumatoid arthritis with total lymphoid irradiation - Long-term survival. ARTHRITIS AND RHEUMATISM, 44(7), 1525-1528.

Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential
Kim, C. H., Kunkel, E. J., Boisvert, J., Johnston, B., Campbell, J. J., & BUTCHER, E. C. (2001). Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. JOURNAL OF CLINICAL INVESTIGATION, 107(5), 595-601.

Current management of rheumatoid arthritis
Genovese, M. C., & Davis, J. S. (2001). Current management of rheumatoid arthritis. HOSPITAL PRACTICE, 36(2), 21-?.

A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues.
Pan, J., Kunkel, E. J., Gosslar, U., Lazarus, N., Langdon, P., & Soler, D. (2000). A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. Journal of immunology , 165(6), 2943-2949.

Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity
Kunkel, E. J., Campbell, J. J., Haraldsen, G., Pan, J. L., Boisvert, J., & Agace, W. W. (2000). Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. JOURNAL OF EXPERIMENTAL MEDICINE, 192(5), 761-767.

Joint and soft-tissue injection - A useful adjuvant to systemic and local treatment
Genovese, M. C. (1998). Joint and soft-tissue injection - A useful adjuvant to systemic and local treatment. POSTGRADUATE MEDICINE, 103(2), 125-?.

Fever, rash, and arthritis in a woman with silicone gel breast implants
Genovese, M. C. (1997). Fever, rash, and arthritis in a woman with silicone gel breast implants. WESTERN JOURNAL OF MEDICINE, 167(3), 149-158.

Lemierre's syndrome
Lee, B. K., LOPEZ, F., Genovese, M., & Loutit, J. S. (1997). Lemierre's syndrome. SOUTHERN MEDICAL JOURNAL, 90(6), 640-643.